Compare McKesson Corporation (MCK) vs Mondaycom Ltd (MNDY) Price & Performance

McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.

MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.

Monday.com (MNDY) trades at $85.95, down 3.01% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $1.48 versus $1.11 expected, and revenue growth of 22% year-over-year. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target.

Outlook is cautiously optimistic due to robust earnings beats and AI product growth, but near-term risks include slower revenue guidance and competitive pressures. The high P/E of 37.04 suggests premium valuation, demanding sustained execution. Investors should weigh strong profitability against guidance concerns for balanced exposure.